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Abstract:
Objective: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by transient or persistent decrease 
of the platelet count to less than 100x109/L. Although it is included in a benign disease group, bleeding complications may 
be mortal. With a better understanding of the pathophysiology of the disease, thrombopoietin receptor agonists, which came 
into use in recent years, seem to be an effective option in the treatment of resistant cases. This study aimed to retrospectively 
assess the efficacy, long-term safety, and tolerability of eltrombopag in Turkish patients with chronic ITP in the Aegean region 
of Turkey.
Materials and Methods: Retrospective data of 40 patients with refractory ITP who were treated with eltrombopag in the 
Aegean region were examined and evaluated.
Results: The total rate of response was 87%, and the median duration of response defined as the number of the platelets 
being over 50x109/L was 19.5 (interquartile range: 5-60) days. In one patient, venous sinus thrombosis was observed with no 
other additional risk factors due to or related to thrombosis. Another patient with complete response and irregular follow-up 
for 12 months was lost due to sudden death as the result of probable acute myocardial infarction.
Conclusion: Although the responses to eltrombopag were satisfactory, patients need to be monitored closely for overshooting 
platelet counts as well as thromboembolic events.
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Introduction
Immune thrombocytopenia (ITP) is an acquired 
autoimmune disease in which antiplatelet antibodies accelerate 
the destruction of platelets in the reticuloendothelial system 
and is characterized by impaired platelet production, resulting 
in low platelet counts [1]. Among adults, about 50 new cases 
of ITP per million are diagnosed per year [2]. In adults, the 
course of the disease is commonly chronic. The primary goal 
of treatment is to prevent bleeding by increasing the platelet 
count to a stable level while managing the few treatment-related 
toxic effects. Current guidelines suggest that treatment should 
only be considered in symptomatic patients with platelet 
counts of less than 30x109/L. Treatment is rarely indicated 
for patients with platelets of >50x109/L in the absence of 
bleeding or predisposing comorbid conditions [1,3]. The first-
line treatment for ITP is glucocorticosteroids. For patients 
who are actively bleeding or who have a contraindication 
to glucocorticosteroids, intravenous immunoglobulin or 
anti-D globulin can be used [4]. These drugs increase 
platelet counts primarily by reducing the extent of platelet 
destruction by several different mechanisms. In the case of 
glucocorticosteroid treatment failure, splenectomy is the main 
second-line therapy and induces a 70%-80% response rate [5]. 
Until recently, in patients who were refractory to or relapsing 
after splenectomy or when splenectomy was contraindicated, 
a variety of immunosuppressive or cytotoxic drugs (such as 
vincristine, cyclophosphamide, azathioprine, cyclosporine 
A, and rituximab) were common as the third-line therapy. 
However, almost 30% of adults with ITP fail to respond to 
these therapies and eventually develop a chronic refractory 
disease [2,6,7]. All of these treatments mainly reduce 
destruction of antibody-coated platelets; however, treatment 
is not always effective and can be restricted by adverse effects. 
ITP is often considered as benign disorder, but health-related 
quality of life is poor. Most of the treatment strategies, such as 
glucocorticosteroids and immunosuppressive drugs, adversely 
affect quality of life. In recent years, a better understanding of 
the pathophysiology of ITP has demonstrated the impaired 
thrombopoiesis and has led to the development of new 
therapeutic approaches. A new approach to the treatment of 
ITP is based on platelet production rather than destruction of 
platelets. Eltrombopag is an oral, nonpeptide, thrombopoietin 
receptor (TPO-R) agonist, approved in several countries for 
the treatment of chronic ITP. Eltrombopag increases platelet 
production by interacting with the transmembrane domain of 
the TPO-R and inducing proliferation and differentiation of 
bone marrow progenitor cells in the megakaryocyte lineage 
[8,9]. It can be prescribed in Turkey since November 2011. 
In this study we aimed to retrospectively assess the efficacy, 
long-term safety, and tolerability of eltrombopag in Turkish 
patients with chronic ITP in the Aegean region of Turkey.
Materials and Methods
This study was designed as a retrospective study. A total of 
40 patients who received eltrombopag treatment for refractory 
chronic ITP at 8 different centers in the Aegean region of 
Turkey were included. 
ITP diagnosis was verified according to the International 
Consensus Report on the Investigation and Management of 
Primary ITP [1]. Primary ITP requires only the finding of 
isolated thrombocytopenia (100x109/L) with no obvious 
associated medical condition [1]. Patients were aged 18 
years and older and had primary ITP of more than 6 months’ 
duration, had baseline platelet counts of lower than 30,000/
µL, and had relapsed after one or more previous treatments for 
their disorder. The form prepared for the study was sent to all 
centers. Date of the first diagnosis of the patients, demographic 
data, time to splenectomy, previous treatments and response 
to treatments, side effects, posttreatment follow-up period, 
and other such records were retrospectively evaluated. The 
Özdemirkıran F, et al: Eltrombopag for the Treatment of Immune Thrombocytopenia
Öz:
Amaç: İmmün trombositopeni (İTP), trombositlerin immün aracılı yıkım ile kalıcı veya geçici olarak 100x109/L altında olduğu 
bir hastalıktır. Selim hematolojik hastalıklar içinde yer almasına rağmen kanama komplikasyonları ölümcül olabilir. Hastalığın 
patofizyolojisi daha iyi anlaşılması ile son yıllarda kullanıma giren trombopoetin reseptör agonistleri, dirençli hastaların 
tedavisinde etkili bir seçenek olarak görünmektedir.
Gereç ve Yöntemler: Bu çalışmada Ege Bölgesi’nde refrakter İTP tanısı ile eltrombopag ile tedavi edilen 8 farklı merkezden 40 
hastanın retrospektif verileri incelenmiş ve değerlendirilmiştir. 
Bulgular: Çalışmada toplam yanıt oranı %87 idi ve trombositlerin 50x109/L’nin üzerine çıktığı medyan süre 19,5 (5-60) gün 
saptandı. Tromboz için başka hiçbir ek risk faktörü bulunmayan bir hastada venöz sinüs trombozu gözlendi. On iki aydır tam yanıtlı 
izlenen ve düzensiz takibe gelen bir diğer hasta olası akut miyokard infarktüsü sonucu gelişen ani ölüm nedeni ile kaybedildi.
Sonuç: Her ne kadar eltrombopag yanıtları tatmin edici olsa da, hızlı ilerleyen trombositemiye bağlı gelişecek tromboembolik 
olaylar açısından, yakın takip ve monitorizasyon gereklidir. 
Anahtar Sözcükler: İmmün trombositopeni, Trombopoetin reseptor agonisti, Kanama, Eltrombopag
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most recent patient data were recorded in December 2013. 
Bleeding was assessed with the World Health Organization 
bleeding scale (grade 0: no bleeding, grade 1: petechiae, 
grade 2: mild blood loss, grade 3: gross blood loss, grade 4: 
debilitating blood loss) [10]. Response rates were defined 
as follows: complete response when the platelet count was 
100x109/L, partial response when the platelet count ranged 
between 30 and 100x109/L with at least a 2-fold increase in 
the initial platelet count, and no response when the platelet 
count was 30x109/L [3]. 
Statistical Analysis
Statistical analysis was performed using SPSS 18.0 (SPSS 
Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was 
used to evaluate the distribution of data. Data with normal 
distribution were reported as mean ± standard deviation (SD), 
while data with nonnormal distribution and nonparametric 
data were reported as medians (interquartile ranges, 25%-
75%). To evaluate effect of baseline platelet counts on treatment 
by eltrombopag, the Mann-Whitney U test was used. For 
comparison of categorical variables, Pearson’s chi-square test 
was used, or in the case of small frequencies, Fisher’s exact 
test was used. Statistical significance was defined as p<0.05.
Results
In total, 40 patients, 30 of them women, from 8 centers 
in the Aegean region of Turkey were included in the study. 
All of them had received glucocorticosteroids at various doses 
as first-line treatment, and splenectomy was implemented in 
28 cases as second-line treatment due to resistance against 
steroid treatment. Splenectomy was not implemented in 12 
cases because of incompatibility for surgery due to comorbid 
disease or the patient’s disapproval. Prior to eltrombopag 
treatment, bleeding scale scores were evaluated for each patient 
and previous treatment numbers were revised and recorded 
(Figure 1). Median previous treatment number was found 
to be 3 (interquartile range: 3-4) (Figure 2). Eltrombopag 
was initiated at 50 mg/day for all patients and the dose was 
regulated in accordance with their response to treatment. The 
distribution of the last drug dose is given in Figure 3. Treatment 
was stopped in 5 cases since no response was obtained. Two 
patients were lost due to intracranial hemorrhage in the first 
month of the treatment. Patient characteristics are reported in 
Table 1.
Mean platelet count before treatment was 11.5x109/
L±8.3x109/L. The total rate of response was 87% and in the 
cases with response the median period in which the number 
of platelets reached over 50x109/L was determined as 19.5 
(interquartile range: 5-60) days (Table 2).
As for response to treatment, whether or not there was 
any sex-related difference was studied by chi-square test; 
no significant difference was determined for response to 
treatment (p=0.629). Whether the baseline platelets had any 
significance in patients’ response to treatment was analyzed 
by Mann-Whitney U test and it was seen that baseline platelet 
count was not important in response to treatment (p=0.531). 
From the viewpoint of response to eltrombopag treatment, the 
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Figure 1. Bleeding data of the patients prior to eltrombopag 
treatment.
No bleeding
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Figure 2. Number of treatments prior to eltrombopag.
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Figure 3. Eltrombopag requirement of patients.
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patients having had splenectomy and those who had not were 
compared by chi-square test. No difference was determined 
between the patients with and without splenectomy in their 
response to eltrombopag treatment (p=0.370).
In the 21 cases in which bone marrow biopsy was done 
prior to treatment, bone marrow reticulin was evaluated in 2 
cases as 2, in 3 cases as 1, and in 16 cases as 0. During treatment, 
none of the patients showed any clinical or laboratory findings 
suggesting increased bone marrow reticulin and bone marrow 
biopsy was not repeated. Adverse effects due to treatment are 
summarized in Table 3. Of the cases with response to treatment, 
drug-related nausea developed in 2 cases and headache in 4 
cases. However, drug use was continued and these adverse 
effects vanished in a few weeks after the beginning of the 
treatment. Platelet count was below 50x109/L on the 7th day 
of treatment in a case in which erythromelalgia developed, 
whereas on the 13th day it reached 580x109/L. However, 
it receded back to the baseline value about 2 weeks after 
termination of drug use. The patient was suggested to start the 
drug again with a lower dose but refused the treatment. One 
male patient at the age of 35, having venous sinus thrombosis 
and showing no other additional risk factors from the point of 
view of thrombosis, was receiving 50 mg eltrombopag and had 
a platelet value on the 15th day of 680x109/L. Treatment was 
terminated. Platelet counts receded back to below 10x109/L 
in 15 days; due to recurrent epistaxis and intraoral bleedings, 
treatment was resumed with dose regulation and no thrombotic 
attack was observed. 
In another patient, treatment was stopped due to an 
increase in transaminases. Transaminase levels were all 
in normal ranges prior to eltrombopag therapy. Alanine 
transaminase (ALT) and aspartate transaminase (AST) levels 
of this patient had gradually increased while she was on 
eltrombopag. After the ALT level had reached up to 3 times 
the upper normal level, eltrombopag was stopped with a 
presumptive diagnosis of toxic hepatitis possibly related 
to eltrombopag. In order to clarify the etiology of elevated 
transaminases and to be certain about whether this co-
incidence was a side effect of eltrombopag or was another 
concomitant disease, hepatitis serology and autoimmune tests 
were applied. Serology results were all negative considering 
hepatitis A, hepatitis B, and hepatitis C. Antimitochondrial 
antibody was positive with a titer of 1/1000. Liver biopsy was 
applied for further clarification of ongoing transaminitis and 
it revealed autoimmune hepatitis. The elevated transaminases 
were therefore not considered as a side effect of the drug, 
rather being considered as an independent concomitant 
autoimmune disorder. After proper treatment of autoimmune 
hepatitis with steroids and azathioprine, transaminase levels 
decreased to normal ranges. At the same time, platelets counts 
were at a steady level between 50,000 and 70,000/µL with the 
aforementioned immunosuppressive therapy and eltrombopag 
was not reinitiated.
One of the patients with complete response who was 
followed irregularly for 12 months was lost due to sudden 
death as a result of probable acute myocardial infarction. In 
the laboratory tests performed on the same day, the patient’s 
platelets were measured as 120x109/L. Two different patients 
who both had complete response at the beginning of treatment 
but whose platelet counts decreased below 10x109/L in the 8th 
month and 1st year of treatment were found to be taking iron 
supplements and calcium supplements, respectively. These 
patients were warned about drug and diet interactions, and 
their platelet counts increased again to above 100x109/L in 
further follow-up. 
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Table 1. Baseline characteristics of the patients.
Sex (Female/Male) 30/10
Age (years) 46.82±16.35
Baseline platelet count x109/L 11.5±8.3
Final platelet count x109/L 204.8±18.5
Period from diagnosis to 
splenectomy (months)
21±36
Number of previous 
treatments
3 (interquartile range: 3-4)
 
Results are given as mean ± standard deviation.
Table 2. Outcomes of the treatment.
Total rate of response n=34 (87%)
Complete response n=24 (60%)
Partial response n=11 (27%)
No response n=5 (13%)
Number of days with of platelet counts above 50,000 (median) 19.5 (interquartile range: 5-60)
Duration of eltrombopag treatment (months) 13.78±7.51
Posttreatment mean platelet count (n=35) 204,771
327
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Target platelet counts after therapy should be between 
50 and 100x109/L, not normalization. In 2 patients, despite 
platelet counts of 30 to 35x109/L, treatment continued with 
partial response since bleeding symptoms were controlled. 
One patient for whom 4 different treatment options had 
been previously applied with no response, and who was 
progressing with intraoral bleedings recurring frequently, 
received a splenectomy in the 2nd month of eltrombopag 
treatment while platelet counts were over 100x109/L. The 
patient then started follow-up with complete response without 
treatment. Treatment doses in responding patients are given in 
Figure 3. In the patients with response to treatment, average 
follow-up period was evaluated as 13.78±7.51 months.
Discussion
In this retrospective study, we have evaluated the long-
term safety, efficacy, and tolerability of eltrombopag use on 
Turkish patients with chronic ITP. In this study in which the 
data of 40 patients were evaluated retrospectively, the total rate 
of response is 87%, where various different treatment options 
such as steroids, anti-D globulin, splenectomy, intravenous 
immunoglobulin, azathioprine, cyclophosphamide, danazol, 
vincristine, and rituximab were applied with no response 
prior to eltrombopag treatment. This rate was similar to the 
rate of 80% obtained in the study of Katsutani et al., where 
3 years of eltrombopag data from 19 patients were evaluated, 
and to the rate of 69.6% obtained in the study of Tomiyama 
et al. including 23 patients with a placebo control [11,12]. 
In the present study, there was no difference between the 
response rates of patients with and without splenectomy, 
in accordance with the literature [13,14]. Although the 
responses were satisfactory, patients need to be monitored 
closely regarding rapidly progressing thrombocythemia as 
well as thromboembolic events.
Treatment was generally well tolerated and continued, 
except for a patient who developed erythromelalgia in the 
1st month of therapy and another patient who developed 
autoimmune hepatitis in the 6th month. While eltrombopag 
is known to have the ability of increasing transaminases 
[15], treatment was terminated in the patient who developed 
autoimmune hepatitis. However, during follow-up, no decrease 
in transaminases occurred despite discontinuing the drug. 
This situation was thus regarded as a concomitant disease. 
The common side effects of eltrombopag treatment, 
headache and nausea, did not cause any termination in the 
treatment and disappeared spontaneously over time. In 
the literature, the incidence of thromboembolic events was 
reported as 2%-4% during treatment with TPO-R agonists; 
however, the rate of only 1 patient out of 40 having sinus vein 
thrombosis was consistent with the literature [16]. We could 
not obtain detailed information about the patient who was lost 
to acute myocardial infarction in the 12th month of treatment 
while being monitored with full response. 
TPO-R agonists may increase the risk of developing or 
progressing reticulin fiber deposition in the bone marrow 
[17]. For patients on eltrombopag, peripheral blood smears 
should be examined for morphological abnormalities such as 
teardrop cells, nucleated red blood cells, leukoerythroblastic 
pictures, dysplastic changes, or cytopenia [18]. If such 
abnormalities develop or deteriorate, a bone marrow biopsy 
should be performed. A loss of response or failure to maintain 
a platelet response with eltrombopag treatment within the 
recommended dosing range should also prompt a search for 
causative factors such as myelofibrosis [18]. In our study, no 
patients displayed suggestive clinical or laboratory findings 
of significant increases in bone marrow reticulin during 
treatment and bone marrow biopsy was not repeated. The 
average follow-up period in the patients who responded to 
treatment of 13.78±7.51 months was satisfactory; on the other 
hand, close monitoring is recommended for thrombocythemia 
and thromboembolic events. In particular, patients who begin 
treatment should be informed in this regard in detail, and this 
therapy is not recommended for cases that cannot be followed 
closely. A decrease in eltrombopag dosage is recommended 
when platelet counts exceed 200x109/L and should be 
completely stopped if platelet count is over 400x109/L. After 
discontinuation due to thrombocythemia or any other adverse 
effects, patients should be monitored to detect any transient 
decrease in platelet counts and to decide about further 
treatment indication and dose. In the case of response loss 
during follow-up in patients with an initial response, diet-
drug interactions must be questioned in detail. 
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